Immatics N.V. (IMTX) Form 6-K — Oct 26, 2026
Immatics presented new ESMO 2026 data on anzu-cel (IMA203), its PRAME-directed TCR T-cell therapy, in advanced melanoma, showing a confirmed objective response rate of 56% (18/32) with a median duration of response of 14.6 months. Median progression-free survival was 6.1 months and median overall survival was 16.2 months, with 12- and 24-month overall survival rates of 70% and 46% respectively in heavily pre-treated patients.
Key figures
- Data cutoff
- Sept 24, 2025
- Median os months
- 16.2
- Median pfs months
- 6.1
- Os 12month percent
- 70
- Os 24month percent
- 46
- Patients evaluated
- 33
- Confirmed orr percent
- 56
- Late n icaht incidence
- 8 of 33 patients (24%), including 2 grade 3-4
- Median duration of response months
- 14.6
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.